Hence, as we demonstrated, HER2-amplified LUAD samples showed increased immune-related and immune cell-type gene expression profiles (GEPs) compared with the other two cancer groups, especially the HER2-amplified BRCA group. The gene discussed is ERBB2; the disease is cancer.